The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …

High-affinity binding of dihydrotestosterone (DHT) to the androgen receptor (AR) initiates
androgen-dependent gene activation, required for normal male sex development in utero …

Intratumoral synthesis of dihydrotestosterone (DHT) from precursors cannot completely
explain the castration resistance of prostate cancer. We showed that DHT was intratumorally …

Androgen receptor (AR) plays a central role in prostate cancer, and most patients respond to
androgen deprivation therapies, but they invariably relapse with a more aggressive prostate …

The accumulation of high concentrations of signalling androgens within prostate tumours
that progress despite use of androgen-deprivation therapy is a clinically important …

Purpose: It has been recognized for almost a decade that concentrations of signaling
androgens sufficient to activate the androgen receptor are present in castration-resistant …

The majority of prostate cancers (PCa) express high levels of androgen receptor (AR) and
are dependent for their growth on testosterone produced by the testes, which is reduced in …

Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves
intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors. We have …

Androgen-deprivation therapy for prostate cancer (PC) eventually leads to castration-
resistant PC (CRPC). Intratumoral androgen production might contribute to tumor …

Purpose. Prostate cancer that recurs during androgen deprivation therapy is referred to as
androgen-independent. High levels of expression of androgen receptor and androgen …